Targets › CD52
2 programs from 2 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2027.
May play a role in carrying and orienting carbohydrate, as well as having a more specific role. (UniProt, P31358)
Open in Phaseline: the race on CD52, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Alemtuzumab CAMPATH-1 antigen inhibitor | CD52 | Phase 2 | Sickle Cell Disease; Sickle Cell Anemia; Congenital Hemolytic Anemia | Dec 2027 |
| Allogene Therapeutics | ALLO-647 Monoclonal antibody targeting CD52 | CD52 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Jan 2030 |
Sickle Cell Disease (2) Advanced/Metastatic Clear Cell Renal Cell Carcinoma (1) Sickle Cell Anemia (1) Congenital Hemolytic Anemia (1)
mixed (2)
Allogene Therapeutics (1) National Heart, Lung, and Blood Institute (NHLBI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.